Page 214 - Drug Class Review
P. 214
Page 137 of 205
Drug Effectiveness Review Project
To evaluate the safety and efficacy of DON in the management of patients with AD residing in nursing
placebo N/A 24 weeks 105 Diagnosis of possible or probable AD with CVD according to NINCDS/ADRDA; MMSE score between 5 and 26 inclusive; reported frequency of a symptom at least several times a week from NPI-NH; sufficient vision and hearing; resided in nursing home for at least 1 month before study Parkinson’s, VaD or other neurological diseases that could be responsible for the dementia; clinically significant obstructive pulmonary disease; asthma; vitamin B 12 deficiency; recent hematological/oncological disorders, hemiparesis or aphasia due to
Drugs Authors: Tariot et al. 47 Eisai, Inc; Pfizer, Inc Setting: Multi-center (27) donepezil 5 mg/d; 10 mg/d 4 weeks; 20 weeks 103
Alzheimer Year: 2001 Country: US home facilities Study design: RCT Sample size: 208
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
